The histaminergic system: A target for innovative treatments of cognitive deficits;Le système histaminergique: Une cible pour de nouveaux traitements des déficits cognitifs

Therapie

Volumn 65, Issue 5, 2010, Pages 415-422

  Motawaj, Mouhammad ^a   Burban, Aude ^a   Davenas, Elisabeth ^a   Gbahou, Florence ^a   Faucard, Raphaël ^a   Morisset, Séverine ^a   Arrang, Jean Michel ^a  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

Cognition; Histamine neurons; Inverse agonists; Tele methylhistamine

Indexed keywords

HISTAMINE RECEPTOR; HISTAMINE; HISTAMINE AGONIST; HISTAMINE H3 RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; INVERSE AGONISM; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; DRUG DELIVERY SYSTEMS; DRUG INVERSE AGONISM; HISTAMINE; HISTAMINE AGONISTS; HUMANS; NEURONS; RECEPTORS, HISTAMINE H3;

EID: 79953736827     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2010058     Document Type: Article

References (84)

1. Schwartz JC, Arrang JM. Histamine, in Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins; 2002: 179-90.
2. Schwartz JC, Arrang JM, Garbarg M, et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71: 1-51.
3. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49: 253-78. (Pubitemid 27414915)
4. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-7. (Pubitemid 13125123)
5. Arrang JM, Garbarg M, Lancelot JC, et al. Highly potent and selective ligands for histamine H3-receptors. Nature 1987; 327: 117-23. (Pubitemid 17062756)
6. 3-receptors control histamine release in human brain. J Neurochem 1988; 51: 105-8.
7. 3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. Eur J Pharmacol 1989; 164: 1-11. (Pubitemid 19123476)
8. 3 receptor agonist. J Pharmacol Exp Ther 1992; 263: 304-10.
9. 3-receptor antagonist. J Pharmacol Exp Ther 1998; 287: 658-66. (Pubitemid 29133666)
10. 3 heteroreceptors. Fundam Clin Pharmacol 1994; 8: 128-37. (Pubitemid 24103046)
11. 3 receptor and its gene transcripts in rat brain. Neuroscience 2002; 114: 173-93. (Pubitemid 35247499)
12. 3 receptor. Mol Pharmacol 1999; 55: 1101-7. (Pubitemid 29252378)
13. 3 receptor. Eur Neuropsychopharmacol 2001; 11: 441-8. (Pubitemid 33026518)
14. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000; 4: 471-503.
15. 3 receptor responsiveness in mouse brain. J Neurochem 2000; 74: 339-46. (Pubitemid 30012787)
16. Kiviranta T, Tuomisto L, Airaksinen EM. Diurnal and age-related changes in cerebrospinal fluid tele-methylhistamine levels during infancy and childhood. Pharmacol Biochem Behav 1994; 49: 997-1000. (Pubitemid 24376041)
17. Strecker RE, Nalwalk J, Dauphin LJ, et al. Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleepwakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience 2002; 113: 663-70. (Pubitemid 34874690)
18. Chu M, Huang ZL, Qu WM, et al. Extracellular histamine level in the frontal cortex is positively correlated with the amount of wakefulness in rats. Neurosci Res 2004; 49: 417-20. (Pubitemid 38953859)
19. Steininger TL, Alam MN, Gong H, et al. Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res 1999; 840: 138-47. (Pubitemid 29434833)
20. 3- receptor ligands: an electrophysiological study in freely moving cats. Behav Brain Res 2003; 144: 227-41. (Pubitemid 37011182)
21. Sherin JE, Elmquist JK, Torrealba F, et al. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 1998; 18: 4705-21. (Pubitemid 28280179)
22. Sherin JE, Shiromani PJ, McCarley RW, et al. Activation of ventrolateral preoptic neurons during sleep. Science 1996; 271: 216-9.
23. Yang QZ, Hatton GI. Electrophysiology of excitatory and inhibitory afferents to rat histaminergic tuberomammillary nucleus neurons from hypothalamic and forebrain sites. Brain Res 1997; 773: 162-72. (Pubitemid 27521120)
24. Chou TC, Bjorkum AA, Gaus SE, et al. Afferents to the ventrolateral preoptic nucleus. J Neurosci 2002; 22: 977-90. (Pubitemid 34141777)
25. B-receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro. Eur JNeurosci 1999; 11: 1148-54. (Pubitemid 29142175)
26. Bayer L, Eggermann E, Serafin M, et al. Orexins (hypocretins) directly excite tuberomammillary neurons. Eur J Neurosci 2001; 14: 1571-5. (Pubitemid 35463724)
27. Eriksson KS, Sergeeva O, Brown RE, et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001; 21: 9273-9. (Pubitemid 33096871)
28. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-51. (Pubitemid 29402482)
29. Torrealba F, Yanagisawa M, Saper CB. Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. Neuroscience 2003; 119: 1033-44. (Pubitemid 36776453)
30. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435: 6-25. (Pubitemid 32448719)
31. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003; 38: 715-30. (Pubitemid 36694779)
32. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001; 98: 9965-70.
33. Shigemoto Y, Fujii Y, Shinomiya K, et al. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res 2004; 1023: 121-5. (Pubitemid 39195341)
34. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001; 313: 125-8. (Pubitemid 33022586)
35. Parmentier R, Ohtsu H, Djebbara-Hannas Z, et al. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci 2002; 22: 7695-711. (Pubitemid 35386369)
36. Lin JS, Hou Y, Sakai K, et al. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J Neurosci 1996; 16: 1523-37. (Pubitemid 26145931)
37. 1 receptors. Proc Natl Acad Sci USA 1996; 93: 13316-20. (Pubitemid 26382813)
38. 1receptor knockout mice. Proc Natl Acad Sci USA 2006; 103: 4687-92.
39. Sangalli BC. Role of the central histaminergic neuronal system in the CNS toxicity of the first generation H1-antagonists. Prog Neurobiol 1997; 52: 145-57. (Pubitemid 27242704)
40. 1 receptors in human brain. Life Sci 2002; 72: 409-14. (Pubitemid 35452554)
41. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
42. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004; 25: 618-25. (Pubitemid 39458167)
43. 3-receptor ligands in the cat. Brain Res 1990; 523: 325-30. (Pubitemid 20230168)
44. 3 receptor on sleep and wakefulness. Eur J Pharmacol 1991; 205: 283-7.
45. Monti JM, Jantos H, Ponzoni A, et al. Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996; 15: 31-5. (Pubitemid 26233388)
46. 3 receptors. Mol Pharmacol 2002; 62: 389-97. (Pubitemid 34804119)
47. 3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004; 13: 1237-48. (Pubitemid 39359655)
48. Esbenshade TA, Fox GB, CowartMD. Histamine H3receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 2006; 6: 77-88.
49. Fox GB, Pan JB, Esbenshade TA, et al. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 2002; 131: 151-61. (Pubitemid 34143166)
50. Prast H, Argyriou A, Philippu A. Histaminergic neurons facilitate social memory in rats. Brain Res 1996; 734: 316-8. (Pubitemid 26334060)
51. Miyazaki S, Imaizumi M, Onodera K. Effects of thioperamide on the cholinergic system and the step-through passive avoidance test in mice. Methods Find Exp Clin Pharmacol 1995; 17: 653-8. (Pubitemid 26054643)
52. Meguro K, Yanai K, Sakai N, et al. Effects of thioperamide, a histamine H3 antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice. Pharmacol Biochem Behav 1995; 50: 321-5.
53. 3 receptor modulation in the septum on post-training memory processing. Psychopharmacology (Berl) 1998; 140: 279-84. (Pubitemid 28562447)
54. 3 receptor-/- mice. Eur J Neurosci 2004; 19: 1992-6. (Pubitemid 38482588)
55. 3 receptor drugs. Nat Rev Drug Discov 2005; 4: 107-20. (Pubitemid 40277492)
56. Hancock AA. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem Pharmacol 2006; 71: 1103-13. (Pubitemid 43361919)
57. 3 receptor antagonists reach out for the clinic. Drug Discov Today 2005; 10: 1613-27. (Pubitemid 41817610)
58. Morisset S, Traiffort E, Schwartz JC. Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur J Pharmacol 1996; 315: R1-R2. (Pubitemid 26390958)
59. Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 2003; 24: 1-23. (Pubitemid 35454140)
60. Airaksinen MS, Paetau A, Paljarvi L, et al. Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 1991; 44: 465-81.
61. Airaksinen MS, Reinikainen K, Riekkinen P, et al. Neurofibrillary tangles and histamine-containing neurons in Alzheimer hypothalamus. Agents Actions 1991; 33: 104-7.
62. Nakamura S, Takemura M, Ohnishi K, et al.: Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease. Neurosci Lett 1993; 151: 196-9. (Pubitemid 23142359)
63. Saper CB, German DC. Hypothalamic pathology in Alzheimer's disease. Neurosci Lett 1987; 74: 364-70. (Pubitemid 17017971)
64. Simpson J, Yates CM, Watts AG, et al. Congo red birefringent structures in the hypothalamus in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 1988; 14: 381-93.
65. Ishunina TA, van Heerikhuize JJ, Ravid R, et al. Estrogen receptors and metabolic activity in the human tuberomamillary nucleus: changes in relation to sex, aging and Alzheimer's disease. Brain Res 2003; 988: 84-96. (Pubitemid 37289497)
66. Panula P, Rinne J, Kuokkanen K, et al. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 1998; 82: 993-7. (Pubitemid 27502044)
67. Mazurkiewicz-Kwilecki IM, Nsonwah S. Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can J Physiol Pharmacol 1989; 67: 75-8. (Pubitemid 19068116)
68. Schneider C, Risser D, Kirchner L, et al. Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Neurosci Lett 1997; 222: 183-6. (Pubitemid 27079733)
69. Cacabelos R, Yamatodani A, Niigawa H, et al. Brain histamine in Alzheimer's disease. Methods Find Exp Clin Pharmacol 1989; 11: 353-60. (Pubitemid 19141366)
70. 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007; 321: 1032-45. (Pubitemid 46762709)
71. 1 receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 2000; 99: 721-9.
72. BealMF, Growdon JH. CSF neurotransmitter markers in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 259-70. (Pubitemid 17172622)
73. Sjogren M, Wikkelso C, Ostling S, et al. Biological correlates of clinical subgroups of Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 14: 191-7. (Pubitemid 36151486)
74. Prell GD, Green JP. Measurement of histamine metabolites in brain and cerebrospinal fluid provides insights into histaminergic activity. Agents Actions 1994; 41 Spec No: C5-C8. (Pubitemid 24199902)
75. Prell GD, Green JP, Kaufmann CA, et al. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 1995; 14: 93-104.
76. Blennow K, Wallin A, Gottfries CG, et al. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 1992; 13: 107-13.
77. Parnetti L, Gaiti A, Reboldi GP, et al. CSF monoamine metabolites in old age dementias. Mol Chem Neuropathol 1992; 16: 143-57.
78. 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. J Neurol Neurosurg Psychiatry 1991; 54: 672-8.
79. Molchan SE, Lawlor BA, Hill JL, et al. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry 1991; 29: 1110-8.
80. Sheline YI, Miller K, Bardgett ME, et al. Higher cerebrospinal fluidMHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction. Am J Geriatr Psychiatry 1998; 6: 155-61. (Pubitemid 28215128)
81. Raskind MA, Peskind ER, Holmes C, et al. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry 1999; 46: 756-65. (Pubitemid 29460901)
82. Hoogendijk WJ, Feenstra MG, Botterblom MH, et al. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol 1999; 45: 82-91. (Pubitemid 29036436)
83. Szot P, White SS, Greenup JL, et al. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 2006; 26: 467-78. (Pubitemid 43237111)
84. Faucard R, Armand V, Heron A, et al. N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J Neurochem 2006; 98: 1487-96. (Pubitemid 44200440)